What are the effects of 5-MeO-DMT?

The acute effects include ego dissolution — a temporary loss of the sense of a separate self — and suppression of sensory and self-referential processing. The experience is typically contentless: no visual geometry, no entities, no narrative sequences. Duration is 20–45 minutes. What follows in the hours and days after is the integration period, which is where most of the therapeutic work happens.

How is 5-MeO-DMT different from DMT?

N,N-DMT (dimethyltryptamine) binds primarily to 5-HT2A receptors and produces a highly visual, content-rich experience — entities, environments, symbolic sequences — lasting 10–20 minutes when smoked. 5-MeO-DMT acts primarily on 5-HT1A receptors and produces an acute, contentless ego dissolution lasting 20–45 minutes. The pharmacology, phenomenology, and integration requirements are all structurally different.

Is 5-MeO-DMT the same as bufo?

Bufo refers to 5-MeO-DMT extracted from the venom of Incilius alvarius (the Sonoran Desert toad). The active compound is the same — 5-MeO-DMT — but the source differs from synthetic 5-MeO-DMT. Both produce the same pharmacological effects. At Transcend, synthetic 5-MeO-DMT is used — the purity is consistent and the extraction from a living species is not involved.

Does 5-MeO-DMT help with depression and anxiety?

Research in naturalistic settings suggests it may. A 2019 survey by Uthaug et al. found significant reductions in depression and anxiety ratings persisting at four-week follow-up. A 2019 study by Davis et al. found approximately 80% of participants reported improvements. These are naturalistic studies, not randomised controlled trials. Absolute contraindications — including current SSRIs and MAOIs — must be addressed before any ceremony is considered.

Who should not use 5-MeO-DMT?

Absolute contraindications include current SSRIs, SNRIs, or MAOIs without a completed physician-supervised taper; personal or family history of schizophrenia or schizophrenia-spectrum disorder; active mania or untreated bipolar I disorder; significant cardiovascular disease; lithium; pregnancy; and acute psychiatric crisis. The most commonly prescribed antidepressants — SSRIs — are a hard contraindication. A completed, supervised taper is required before any ceremony is considered.

Can I do 5-MeO-DMT if I'm on antidepressants?

Not without a completed, physician-supervised taper first. 5-MeO-DMT in the presence of active SSRI or SNRI activity risks serotonin syndrome — a medical emergency. This is not a risk to weigh against potential benefit; it is a hard contraindication. If you are considering 5-MeO-DMT and are on antidepressants, the starting point is a screening conversation, not a decision to taper on your own.

How long do the effects of 5-MeO-DMT last?

The acute experience is 20–45 minutes. Return to baseline typically happens within an hour. However, the post-experience period — the integration window — can involve shifts in mood, perception, and self-referential processing that last days to weeks. The acute duration is short. The effects on how someone relates to themselves and their experience can be more durable, for better or worse depending on integration.

What Does 5-MeO-DMT Do to Your Brain? The Neuroscience Explained

5-MeO-DMT acts primarily on 5-HT1A serotonin receptors — a binding profile distinct from psilocybin, N,N-DMT, and ibogaine. The result is rapid, intense suppression of the default mode network: the brain's self-referential processing system goes quiet, and the subjective sense of a separate self temporarily dissolves. The experience lasts 20–45 minutes. SSRIs are an absolute contraindication, and the absence of narrative content makes integration harder, not simpler.

5-MeO-DMT binds most powerfully to 5-HT1A serotonin receptors — different from psilocybin or N,N-DMT, which act primarily on 5-HT2A. It also binds sigma-1 receptors and inhibits the serotonin transporter at higher doses. The combined effect is acute suppression of default mode network activity, producing ego dissolution that peaks within minutes and typically resolves within 20–45 minutes.

Dense jungle canopy at dusk — 5-MeO-DMT ceremony takes place in carefully facilitated settings — Photo via Pexels.

The Receptor Profile: 5-HT1A, Not 5-HT2A

The distinction matters because most of what people know about psychedelics is built on the 5-HT2A story. Psilocybin, N,N-DMT, and LSD all act primarily on 5-HT2A receptors in the cortex — the binding site responsible for the visual geometry, the narrative content, the sense that something is being shown to you. That receptor system is not the primary target of 5-MeO-DMT.

5-MeO-DMT's primary affinity is for 5-HT1A receptors — inhibitory receptors concentrated in the limbic system and brainstem rather than the visual cortex. 5-HT1A agonism produces sedation, anxiolysis, and suppression of sensory processing, not amplification of it. At higher doses, 5-MeO-DMT also binds sigma-1 receptors, which are associated with neuroprotection and regulation of the stress response, and inhibits the serotonin transporter (SERT), increasing synaptic serotonin. The combined pharmacology is more suppressive than stimulating — which is what produces the experience of the perceptual field collapsing rather than expanding.

This is why people who have used psilocybin or N,N-DMT and expect 5-MeO-DMT to be a stronger version of the same experience are wrong. It is not a stronger version. It is a different mechanism producing a qualitatively different effect.

The Default Mode Network and Ego Dissolution

The default mode network (DMN) is a set of brain regions that are most active when you are not focused on any specific task — when you are thinking about yourself, planning, ruminating, or processing autobiographical memory. It is the neural correlate of the self-referential mind. Neuroimaging research shows that the DMN is abnormally overactive in depression, PTSD, anxiety, and addiction.

5-MeO-DMT produces acute, profound suppression of DMN activity. The subjective experience of this — what people report as ego dissolution or ego death — is not metaphorical. It corresponds to a measurable reduction in the functional connectivity of the brain networks that generate the ordinary experience of being a distinct self. For 20–45 minutes, the processing system that maintains the narrative of “me” goes quiet.

What returns when it comes back is not always the same as what was there before. That is the period that integration works with. The experience itself is not the treatment — it is the opening for the treatment.

How 5-MeO-DMT Differs from N,N-DMT Neurologically

N,N-DMT (dimethyltryptamine — the compound in ayahuasca, and the one people often mean when they say “DMT”) acts primarily on 5-HT2A receptors. The experience is typically highly visual, narrative, and content-rich — entities, environments, symbolic sequences. Integration after N,N-DMT usually involves working with specific content that arose during the experience.

5-MeO-DMT experiences are typically contentless. There are no entities, no visual environments, no narrative sequences. There is instead an acute loss of bounded self-awareness, sometimes described as merging with the ground of experience, sometimes as whiteness or formlessness, sometimes as terror followed by release. Because there is no narrative content to integrate, the integration process is structurally different — and for some people, harder. There is nothing to interpret. The work is in relating to the self that returned.

5-MeO-DMT is also significantly more potent by weight than N,N-DMT. Effective doses are measured in milligrams rather than tens of milligrams. Onset is faster. The experience is shorter. The intensity is typically described as greater.

What the Research Shows

The research base for 5-MeO-DMT is smaller than for psilocybin but is growing. A 2019 naturalistic survey by Uthaug et al. found significant reductions in depression and anxiety ratings after a single 5-MeO-DMT experience, with improvements persisting at four-week follow-up. A 2019 study by Davis et al. found that approximately 80% of participants reported improvements in depression and anxiety after 5-MeO-DMT, with the majority describing their experience as one of the most meaningful of their lives. Both studies used naturalistic designs rather than randomised controlled trials.

For comparison, the 2023 Stanford study published in Nature Medicine examined ibogaine (a structurally different compound with different receptor pharmacology) in 30 special operations veterans and found 88% reductions in PTSD symptoms, 87% in depression, and 81% in anxiety at one month. These are two distinct medicines. Comparing them directly on the basis of mechanism or effect size requires caution.

What the 5-MeO-DMT literature consistently shows: acute ego dissolution, rapid onset, short duration, and in most participants, a post-experience shift in self-referential processing. Whether that shift produces lasting benefit depends substantially on what happens in the integration period — and on whether the participant was an appropriate candidate to begin with.

What 5-MeO-DMT Does Not Do

5-MeO-DMT does not produce a hallucinogenic experience in the visual-cortex sense. There are no geometric patterns, no entities, no elaborate psychedelic environments. People who expect that are often surprised.

It does not produce an experience that can be navigated. The loss of self-awareness is not like a difficult psilocybin session where grounding is possible and you can work with the content in real time. The 20–45 minutes is not a session. It is, for most people, unremembered in conventional narrative terms.

It does not substitute for integration. The acute experience is the opening. A ceremony without subsequent integration work is a neurological event that produced an unusual brain state. Integration is what determines whether anything lasting emerges from it. Read the integration page for what that involves.

It does not combine safely with SSRIs, MAOIs, or lithium. This is not a caveat — it is a hard constraint. 5-MeO-DMT in the presence of SSRI activity risks serotonin syndrome, which is a medical emergency. No legitimate provider will proceed with ceremony while a participant is on an active SSRI or SNRI without a completed, physician-supervised taper.

See the comparison of iboga and 5-MeO-DMT for more on what each medicine addresses and how they differ as ceremonial tools.

Who Is Not an Appropriate Candidate

This is the most important section of this article. 5-MeO-DMT ceremony is not appropriate for everyone who wants it.

Current SSRIs, SNRIs, or MAOIs without a completed, physician-supervised taper. This is an absolute contraindication. Serotonin syndrome in the presence of 5-MeO-DMT and active SSRI/SNRI is a life-threatening risk. The most commonly prescribed antidepressants in use today are absolute contraindications.
Personal or family history of schizophrenia or schizophrenia-spectrum disorder. The acute ego dissolution of 5-MeO-DMT can destabilise schizophrenia-spectrum presentations in ways that do not reliably resolve within the ceremony window.
Active mania or untreated bipolar I disorder.
Significant cardiovascular disease.5-MeO-DMT produces cardiovascular arousal. This is not the same cardiac profile as ibogaine — ibogaine's cardiac risk is QT prolongation, not the same mechanism — but cardiac screening is still required.
Lithium. The combination of lithium and serotonergic compounds carries a risk of adverse neurological effects. This is a hard contraindication.
Pregnancy.
Acute psychiatric crisis. The absence of narrative content in the experience makes it poorly suited to crisis stabilisation. This is not a medicine for acute destabilisation.

The FAQ covers medical screening in more detail. If you are on antidepressants and considering 5-MeO-DMT, start with the screening conversation — not with the decision to taper on your own.

Is This Right for You?

5-MeO-DMT ceremony at Transcend in Vancouver is for people who have done enough prior work — therapeutic, integrative, or otherwise — that the absence of narrative content in the experience is not an obstacle. It is for people who are not currently on SSRIs or MAOIs, or who have completed a supervised taper. It is not for people who are in acute crisis, who have not done prior inner work, or who are expecting a psychedelic experience in the classic visual sense.

The ceremony page covers the full structure of both iboga and 5-MeO-DMT ceremony at Transcend. The FAQ covers the most common questions about contraindications, screening, and what to expect. If you want to apply, start there, or reach out directly at jake.nylund@gmail.com. Every application receives a personal response within 2–3 business days. No ceremony date is confirmed before medical screening establishes candidacy.